Advances and applications of monoolein as a novel nanomaterial in mitigating chronic lung diseases.

Chan, Y; Singh, SK; Gulati, M; Wadhwa, S; Prasher, P; Kumar, D; Kumar, AP; Gupta, G; Kuppusamy, G; Haghi, M; George Oliver, BG; Adams, J; Chellappan, DK; Dua, K

Advances and applications of monoolein as a novel nanomaterial in mitigating chronic lung diseases.

Chan, Y Singh, SK Gulati, M Wadhwa, S Prasher, P Kumar, D Kumar, AP Gupta, G Kuppusamy, G Haghi, M George Oliver, BG Adams, J Chellappan, DK Dua, K

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: J Drug Deliv Sci Technol, 2022, 74, pp. 103541
Issue Date:: 2022-08

Closed Access

	Filename	Description	Size
	Advances and applications of monoolein as a novel nanomaterial in mitigating chronic lung diseases.pdf		2.79 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Chan, Y
dc.contributor.author	Singh, SK
dc.contributor.author	Gulati, M
dc.contributor.author	Wadhwa, S
dc.contributor.author	Prasher, P
dc.contributor.author	Kumar, D
dc.contributor.author	Kumar, AP
dc.contributor.author	Gupta, G
dc.contributor.author	Kuppusamy, G
dc.contributor.author	Haghi, M
dc.contributor.author	George Oliver, BG
dc.contributor.author	Adams, J
dc.contributor.author	Chellappan, DK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.date.accessioned	2022-07-24T05:41:42Z
dc.date.available	2022-06-20
dc.date.available	2022-07-24T05:41:42Z
dc.date.issued	2022-08
dc.identifier.citation	J Drug Deliv Sci Technol, 2022, 74, pp. 103541
dc.identifier.issn	1773-2247
dc.identifier.issn	2588-8943
dc.identifier.uri	http://hdl.handle.net/10453/159145
dc.description.abstract	Chronic lung diseases such as asthma, chronic obstructive pulmonary disease, lung cancer, and the recently emerged COVID-19, are a huge threat to human health, and among the leading causes of global morbidity and mortality every year. Despite availability of various conventional therapeutics, many patients remain poorly controlled and have a poor quality of life. Furthermore, the treatment and diagnosis of these diseases are becoming increasingly challenging. In the recent years, the application of nanomedicine has become increasingly popular as a novel strategy for diagnosis, treatment, prevention, as well as follow-up of chronic lung diseases. This is attributed to the ability of nanoscale drug carriers to achieve targeted delivery of therapeutic moieties with specificity to diseased site within the lung, thereby enhancing therapeutic outcomes of conventional therapies whilst minimizing the risks of adverse reactions. For this instance, monoolein is a polar lipid nanomaterial best known for its versatility, thermodynamic stability, biocompatibility, and biodegradability. As such, it is commonly employed in liquid crystalline systems for various drug delivery applications. In this review, we present the applications of monoolein as a novel nanomaterial-based strategy for targeted drug delivery with the potential to revolutionize therapeutic approaches in chronic lung diseases.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier BV
dc.relation.ispartof	J Drug Deliv Sci Technol
dc.relation.isbasedon	10.1016/j.jddst.2022.103541
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Pharmacology & Pharmacy
dc.title	Advances and applications of monoolein as a novel nanomaterial in mitigating chronic lung diseases.
dc.type	Journal Article
utslib.citation.volume	74
utslib.location.activity	France
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2022-07-24T05:41:38Z
pubs.publication-status	Published
pubs.volume	74

Abstract:

Chronic lung diseases such as asthma, chronic obstructive pulmonary disease, lung cancer, and the recently emerged COVID-19, are a huge threat to human health, and among the leading causes of global morbidity and mortality every year. Despite availability of various conventional therapeutics, many patients remain poorly controlled and have a poor quality of life. Furthermore, the treatment and diagnosis of these diseases are becoming increasingly challenging. In the recent years, the application of nanomedicine has become increasingly popular as a novel strategy for diagnosis, treatment, prevention, as well as follow-up of chronic lung diseases. This is attributed to the ability of nanoscale drug carriers to achieve targeted delivery of therapeutic moieties with specificity to diseased site within the lung, thereby enhancing therapeutic outcomes of conventional therapies whilst minimizing the risks of adverse reactions. For this instance, monoolein is a polar lipid nanomaterial best known for its versatility, thermodynamic stability, biocompatibility, and biodegradability. As such, it is commonly employed in liquid crystalline systems for various drug delivery applications. In this review, we present the applications of monoolein as a novel nanomaterial-based strategy for targeted drug delivery with the potential to revolutionize therapeutic approaches in chronic lung diseases.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/159145